Phase II Study of Everolimus Beyond Progression
Summary
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement (recurred) on everolimus and exemestane hormone therapy. Everolimus is a chemotherapy drug that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen and progesterone are hormones that can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by lowering the amount of estrogen and progesterone the body makes. Giving everolimus with a different type of hormone therapy may be an effective treatment for breast cancer in patients who progressed on everolimus with exemestane.
Timeline
- Start
- 2014-11-25
- Primary completion
- 2021-01-25
- Completion
- 2021-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | Oral |
| Background | Anastrozole | Other / unclassified | — | Oral |
| Background | Fulvestrant | Small molecule | — | Intramuscular |
| Background | Letrozole | Other / unclassified | — | Oral |
| Background | Megestrol Acetate | Other / unclassified | — | Oral |
| Background | Tamoxifen | Small molecule | — | Oral |